M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
FRA:M12 - Deutsche Boerse Ag - DE000A0STSQ8 - Common Stock - Currency: EUR
Overall M12 gets a fundamental rating of 6 out of 10. We evaluated M12 against 24 industry peers in the Health Care Providers & Services industry. M12 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. M12 is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes M12 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
In the past year M12 had a positive cash flow from operations.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
M12 has a Return On Assets of 8.53%. This is amongst the best in the industry. M12 outperforms 95.83% of its industry peers.
With a decent Return On Equity value of 15.10%, M12 is doing good in the industry, outperforming 79.17% of the companies in the same industry.
The Return On Invested Capital of M12 (12.86%) is better than 95.83% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 6.16%.
The last Return On Invested Capital (12.86%) for M12 is above the 3 year average (7.72%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.53% | ||
| ROE | 15.1% | ||
| ROIC | 12.86% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
Looking at the Profit Margin, with a value of 4.72%, M12 is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
M12's Profit Margin has declined in the last couple of years.
M12 has a Operating Margin of 7.89%. This is in the better half of the industry: M12 outperforms 62.50% of its industry peers.
M12's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 18.75%, M12 is doing worse than 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.89% | ||
| PM (TTM) | 4.72% | ||
| GM | 18.75% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M12 is creating value.
M12 has less shares outstanding than it did 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
M12 has an Altman-Z score of 5.29. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
M12's Altman-Z score of 5.29 is amongst the best of the industry. M12 outperforms 95.83% of its industry peers.
The Debt to FCF ratio of M12 is 0.71, which is an excellent value as it means it would take M12, only 0.71 years of fcf income to pay off all of its debts.
M12 has a better Debt to FCF ratio (0.71) than 100.00% of its industry peers.
M12 has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
M12 has a better Debt to Equity ratio (0.07) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.71 | ||
| Altman-Z | 5.29 |
ROIC/WACC1.81
WACC7.1%
2.3 Liquidity
M12 has a Current Ratio of 1.91. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.91, M12 belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
A Quick Ratio of 1.07 indicates that M12 should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.07, M12 is in line with its industry, outperforming 54.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.90% over the past year.
Measured over the past 5 years, M12 shows a small growth in Earnings Per Share. The EPS has been growing by 7.97% on average per year.
Looking at the last year, M12 shows a small growth in Revenue. The Revenue has grown by 7.23% in the last year.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)55.9%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%-10.77%
Revenue 1Y (TTM)7.23%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%3.58%
3.2 Future
The Earnings Per Share is expected to grow by 19.66% on average over the next years. This is quite good.
The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y15.41%
EPS Next 2Y19.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.37%
Revenue Next 2Y7.19%
Revenue Next 3Y7.36%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.80, the valuation of M12 can be described as rather expensive.
M12's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of M12 to the average of the S&P500 Index (27.30), we can say M12 is valued slightly cheaper.
A Price/Forward Earnings ratio of 15.04 indicates a correct valuation of M12.
M12's Price/Forward Earnings is on the same level as the industry average.
M12 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.8 | ||
| Fwd PE | 15.04 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, M12 is valued a bit cheaper than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.7 | ||
| EV/EBITDA | 8.78 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
M12 has a very decent profitability rating, which may justify a higher PE ratio.
M12's earnings are expected to grow with 19.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.16
PEG (5Y)2.24
EPS Next 2Y19.66%
EPS Next 3YN/A
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.35%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.77, M12 pays a better dividend. On top of this M12 pays more dividend than 91.67% of the companies listed in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.35% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y19.66%
EPS Next 3YN/A
FRA:M12 (7/8/2025, 7:00:00 PM)
14.6
-0.42 (-2.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap286.74M
Analysts85
Price Target26.52 (81.64%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.35% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.8 | ||
| Fwd PE | 15.04 | ||
| P/S | 0.85 | ||
| P/FCF | 9.7 | ||
| P/OCF | 9.39 | ||
| P/B | 2.7 | ||
| P/tB | 15.39 | ||
| EV/EBITDA | 8.78 |
EPS(TTM)0.82
EY5.62%
EPS(NY)0.97
Fwd EY6.65%
FCF(TTM)1.5
FCFY10.31%
OCF(TTM)1.56
OCFY10.65%
SpS17.27
BVpS5.4
TBVpS0.95
PEG (NY)1.16
PEG (5Y)2.24
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.53% | ||
| ROE | 15.1% | ||
| ROCE | 18.56% | ||
| ROIC | 12.86% | ||
| ROICexc | 15.5% | ||
| ROICexgc | 57.73% | ||
| OM | 7.89% | ||
| PM (TTM) | 4.72% | ||
| GM | 18.75% | ||
| FCFM | 8.71% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexcg growth 3Y38.16%
ROICexcg growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.71 | ||
| Debt/EBITDA | 0.23 | ||
| Cap/Depr | 19.3% | ||
| Cap/Sales | 0.29% | ||
| Interest Coverage | 17.5 | ||
| Cash Conversion | 95.72% | ||
| Profit Quality | 184.48% | ||
| Current Ratio | 1.91 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | 5.29 |
F-Score9
WACC7.1%
ROIC/WACC1.81
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)55.9%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%-10.77%
EPS Next Y15.41%
EPS Next 2Y19.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.23%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%3.58%
Revenue Next Year6.37%
Revenue Next 2Y7.19%
Revenue Next 3Y7.36%
Revenue Next 5Y8.24%
EBIT growth 1Y69.16%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year28.34%
EBIT Next 3Y33.77%
EBIT Next 5YN/A
FCF growth 1Y49.16%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y46.7%
OCF growth 3Y24.88%
OCF growth 5YN/A